SEL PHARMACIE DE LA TUILERIE : revenue, balance sheet and financial ratios

SEL PHARMACIE DE LA TUILERIE is a French company founded 26 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MULHOUSE (68200), this company of category PME shows in 2016 a revenue of 1.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SEL PHARMACIE DE LA TUILERIE (SIREN 429375769)
Indicator 2023 2022 2020 2019 2018 2017 2016 2015 2014
Revenue N/C N/C N/C N/C N/C N/C 1 600 525 € 1 600 312 € 1 515 133 €
Net income 47 284 € 94 394 € 36 785 € 22 299 € 31 418 € 19 311 € 24 643 € 48 221 € 205 017 €
EBITDA N/C N/C N/C N/C N/C N/C 76 € 37 286 € -34 765 €
Net margin N/C N/C N/C N/C N/C N/C 1.5% 3.0% 13.5%

Revenue and income statement

In 2023, SEL PHARMACIE DE LA TUILERIE generates positive net income of 47 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2014-2023: 205 k€ -> 47 k€.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

47 284 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 70%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 52%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

69.576%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

52.471%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

47.3%

Solvency indicators evolution
SEL PHARMACIE DE LA TUILERIE

Sector positioning

Debt ratio
69.58 2023
2020
2022
2023
Q1: 20.09
Med: 66.92
Q3: 169.24
Average +9 pts over 3 years

In 2023, the debt ratio of SEL PHARMACIE DE LA TUILERIE (69.58) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
52.47% 2023
2020
2022
2023
Q1: 28.72%
Med: 48.51%
Q3: 68.17%
Good -8 pts over 3 years

In 2023, the financial autonomy of SEL PHARMACIE DE LA TUILERIE (52.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 206.87. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

206.865

Liquidity indicators evolution
SEL PHARMACIE DE LA TUILERIE

Sector positioning

Liquidity ratio
206.87 2023
2020
2022
2023
Q1: 135.23
Med: 189.76
Q3: 270.17
Good -20 pts over 3 years

In 2023, the liquidity ratio of SEL PHARMACIE DE LA TUILERIE (206.87) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 407 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 783 days. Excellent situation: suppliers finance 376 days of the operating cycle (retail model).

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

407 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

783 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SEL PHARMACIE DE LA TUILERIE

Positioning of SEL PHARMACIE DE LA TUILERIE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 220 transactions of similar company sales in 2023, the value of SEL PHARMACIE DE LA TUILERIE is estimated at 557 926 € (range 339 301€ - 784 319€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
220 transactions
339k€ 557k€ 784k€
557 926 € Range: 339 301€ - 784 319€
NAF 5 année 2023

Valuation method used

Net Income Multiple
47 284 € × 11.8x = 557 926 €
Range: 339 302€ - 784 319€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SEL PHARMACIE DE LA TUILERIE with other companies in the same sector:

Frequently asked questions about SEL PHARMACIE DE LA TUILERIE

What is the revenue of SEL PHARMACIE DE LA TUILERIE ?

The revenue of SEL PHARMACIE DE LA TUILERIE in 2016 is 1.6 M€.

Is SEL PHARMACIE DE LA TUILERIE profitable?

Yes, SEL PHARMACIE DE LA TUILERIE generated a net profit of 47 k€ in 2023.

Where is the headquarters of SEL PHARMACIE DE LA TUILERIE ?

The headquarters of SEL PHARMACIE DE LA TUILERIE is located in MULHOUSE (68200), in the department Haut-Rhin.

Where to find the tax return of SEL PHARMACIE DE LA TUILERIE ?

The tax return of SEL PHARMACIE DE LA TUILERIE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SEL PHARMACIE DE LA TUILERIE operate?

SEL PHARMACIE DE LA TUILERIE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.